JMP Securities analyst Silvan Tuerkcan downgraded Intellia Therapeutics to Market Perform from Outperform without a price target. The analyst views the shares as fairly valued at current levels. Moving in-vivo editing to the U.S. will represent a major milestone, but there is little upside for the stock with more downside risk as the company engages regulators, Tuerkcan tells investors in a research note. The analyst says 2023 will bring little in terms of clinical updates for Intellia with the focus on regulatory interactions.